Armata Pharmaceuticals, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
ARMP$3.51+17.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| | March 31, 2025 | December 31, 2024 | ||||
| Assets | | | | | | |
| Current assets | | | | | | |
| Cash and cash equivalents | | $11,688 | | $9,291 | ||
| Prepaid expenses and other current assets | | 1,240 | | 1,273 | ||
| Other receivables | | | 238 | | | 744 |
| Total current assets | | 13,166 | | 11,308 | ||
| Restricted cash | | | 5,390 | | | 5,480 |
| Property and equipment, net | | 12,883 | | 13,241 | ||
| Operating lease right-of-use asset | | 41,090 | | 41,687 | ||
| In-process research and development | | | 10,256 | | | 10,256 |
| Goodwill | | | 3,490 | | | 3,490 |
| Other assets | | 975 | | 975 | ||
| Total assets | | $87,250 | | $86,437 | ||
| | | | | | | |
| Liabilities and stockholders’ deficit | | | ||||
| Current liabilities | | | ||||
| Accounts payable and accrued liabilities | | $1,614 | | $2,055 | ||
| Accrued compensation | | | 1,347 | | | 2,280 |
| Convertible Loan, current | | | 27,694 | | | — |
| Term debt, current | | | 75,089 | | | 38,954 |
| Current portion of operating lease liabilities | | | 4,459 | | | 4,431 |
| Other current liabilities | | | 337 | | | 529 |
| Total current liabilities | | 110,540 | | 48,249 | ||
| Convertible Loan, non-current | | | — | | | 32,897 |
| Term debt, non-current | | | — | | | 22,539 |
| Operating lease liabilities, net of current portion | | | 27,416 | | | 27,694 |
| Deferred tax liability | | | 3,077 | | | 3,077 |
| Total liabilities | | 141,033 | | 134,456 | ||
| | | | | | | |
| Commitments and contingencies (Note 12) | | | ||||
| Stockholders’ deficit | | | ||||
| Common Stock, $0.01 par value; 217,000,000 shares authorized; 36,193,479 and 36,183,067 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | | 362 | | 362 | ||
| Additional paid-in capital | | 280,121 | | 279,354 | ||
| Accumulated deficit | | (334,266) | | (327,735) | ||
| Total stockholders’ deficit | | (53,783) | | (48,019) | ||
| Total liabilities and stockholders’ deficit | | $87,250 | | $86,437 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.